Technical Analysis for VCNX - Vaccinex, Inc.

Grade Last Price % Change Price Change
F 2.35 -2.89% -0.07
VCNX closed down 3.59 percent on Thursday, April 15, 2021, on 6 percent of normal volume. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a bounce should not be unexpected.

Trend Table & Recent EOD Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Down Down Down
Historical VCNX trend table...

Date Alert Name Type % Chg
Wide Bands Range Expansion -2.89%
Oversold Stochastic Weakness -2.89%
Stochastic Buy Signal Bullish -6.37%
Narrow Range Bar Range Contraction -6.37%
Wide Bands Range Expansion -6.37%
Oversold Stochastic Weakness -6.37%
Narrow Range Bar Range Contraction -7.48%
Inside Day Range Contraction -7.48%
Wide Bands Range Expansion -7.48%
Oversold Stochastic Weakness -7.48%
Older End-of-Day Signals for VCNX ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
60 Minute Opening Range Breakout about 2 hours ago
Lower Bollinger Band Support about 2 hours ago
Down 5% about 2 hours ago
Down 3% about 2 hours ago
Down 2 % about 2 hours ago
View Earlier Intraday Alerts

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.


Vaccinex, Inc. Description

Vaccinex Inc. is a clinical-stage biotechnology company engaged in the discovery and development of targeted biotherapeutics. The Company is focused on providing treatments for serious diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. It provides SEMA4D antibody platform, which is focused on developing its lead product candidate VX15/2503 (VX15) for the treatment of non-small cell lung cancer, NSCLC, osteosarcoma, melanoma and Huntington’s disease. It also provides ActiveMAb antibody discovery platform, a human antibody discovery platform used for expressing large and diverse libraries of high affinity, full-length human monoclonal antibodies on the surface of vaccinia, a mammalian virus. Its product candidate VX5 is in preclinical development for the treatment of multiple sclerosis and potentially for other autoimmune disorders.


Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Cancer Biology Immunology Clinical Development Immune System Antibodies Monoclonal Antibodies Small Cell Lung Cancer Antibody Melanoma Non Small Cell Lung Cancer Multiple Sclerosis Degenerative Disease Degenerative Diseases Sarcoma Serious Diseases Immune Disorders Neurodegenerative Diseases Autoimmune Disorders Treatment Of Non Small Cell Lung Cancer Nsclc Human Monoclonal Antibodies Osteosarcoma Tolerx Treatment Of Multiple Sclerosis Seth Lederman Vaccinia

Is VCNX a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength


Indicator Value
52 Week High 9.56
52 Week Low 1.63
Average Volume 6,729,277
200-Day Moving Average 3.39
50-Day Moving Average 3.25
20-Day Moving Average 2.96
10-Day Moving Average 2.71
Average True Range 0.27
ADX 20.66
+DI 21.05
-DI 27.30
Chandelier Exit (Long, 3 ATRs ) 3.33
Chandelier Exit (Short, 3 ATRs ) 3.20
Upper Bollinger Band 3.58
Lower Bollinger Band 2.33
Percent B (%b) 0.07
BandWidth 42.10
MACD Line -0.21
MACD Signal Line -0.15
MACD Histogram -0.0604
Fundamentals Value
Market Cap 54.17 Million
Num Shares 22.4 Million
EPS -3.01
Price-to-Earnings (P/E) Ratio -0.80
Price-to-Sales 705.84
Price-to-Book 0.00
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 2.68
Resistance 3 (R3) 2.69 2.62 2.63
Resistance 2 (R2) 2.62 2.56 2.61 2.62
Resistance 1 (R1) 2.52 2.51 2.49 2.51 2.60
Pivot Point 2.45 2.45 2.43 2.44 2.45
Support 1 (S1) 2.35 2.39 2.32 2.34 2.24
Support 2 (S2) 2.28 2.34 2.27 2.22
Support 3 (S3) 2.18 2.28 2.21
Support 4 (S4) 2.17